Tags

Type your tag names separated by a space and hit enter

From endocannabinoid profiling to 'endocannabinoid therapeutics'.
Curr Opin Chem Biol 2009; 13(3):321-31CO

Abstract

The discovery of the endocannabinoid signalling system, that is, of cannabinoid receptors, their endogenous ligands, known as endocannabinoids, and of endocannabinoid anabolic and catabolic enzymes, raised several questions regarding the physiopathological role of these mediators. Several of these questions were answered by investigating alterations in the levels of the most studied endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), in tissues of animal models of disorders, and in bioptic samples and biological fluids (cerebrospinal fluid and blood) of human volunteers. Subsequently, the pharmacological effects of synthetic compounds that selectively target the cannabinoid CB(1) and CB(2) receptors, and endocannabinoid anabolic and catabolic enzymes, established cause-effect relationships between pathological alterations in endocannabinoid levels and the symptoms and progress of several disorders, including emesis, obesity, metabolic disorders, hepatic diseases, pain, inflammation and neurological and neuropsychiatric disorders. These new developments are discussed in this second review on the endocannabinoids, together with the results of pre-clinical and clinical studies on the potential therapeutic use of plant-derived cannabinoids and synthetic agents that manipulate pharmacologically the action at cannabinoid receptors or the tissue levels of AEA and 2-AG.

Authors+Show Affiliations

Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19497779

Citation

Ligresti, Alessia, et al. "From Endocannabinoid Profiling to 'endocannabinoid Therapeutics'." Current Opinion in Chemical Biology, vol. 13, no. 3, 2009, pp. 321-31.
Ligresti A, Petrosino S, Di Marzo V. From endocannabinoid profiling to 'endocannabinoid therapeutics'. Curr Opin Chem Biol. 2009;13(3):321-31.
Ligresti, A., Petrosino, S., & Di Marzo, V. (2009). From endocannabinoid profiling to 'endocannabinoid therapeutics'. Current Opinion in Chemical Biology, 13(3), pp. 321-31. doi:10.1016/j.cbpa.2009.04.615.
Ligresti A, Petrosino S, Di Marzo V. From Endocannabinoid Profiling to 'endocannabinoid Therapeutics'. Curr Opin Chem Biol. 2009;13(3):321-31. PubMed PMID: 19497779.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - From endocannabinoid profiling to 'endocannabinoid therapeutics'. AU - Ligresti,Alessia, AU - Petrosino,Stefania, AU - Di Marzo,Vincenzo, Y1 - 2009/06/03/ PY - 2009/03/17/received PY - 2009/04/17/accepted PY - 2009/6/6/entrez PY - 2009/6/6/pubmed PY - 2009/10/1/medline SP - 321 EP - 31 JF - Current opinion in chemical biology JO - Curr Opin Chem Biol VL - 13 IS - 3 N2 - The discovery of the endocannabinoid signalling system, that is, of cannabinoid receptors, their endogenous ligands, known as endocannabinoids, and of endocannabinoid anabolic and catabolic enzymes, raised several questions regarding the physiopathological role of these mediators. Several of these questions were answered by investigating alterations in the levels of the most studied endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG), in tissues of animal models of disorders, and in bioptic samples and biological fluids (cerebrospinal fluid and blood) of human volunteers. Subsequently, the pharmacological effects of synthetic compounds that selectively target the cannabinoid CB(1) and CB(2) receptors, and endocannabinoid anabolic and catabolic enzymes, established cause-effect relationships between pathological alterations in endocannabinoid levels and the symptoms and progress of several disorders, including emesis, obesity, metabolic disorders, hepatic diseases, pain, inflammation and neurological and neuropsychiatric disorders. These new developments are discussed in this second review on the endocannabinoids, together with the results of pre-clinical and clinical studies on the potential therapeutic use of plant-derived cannabinoids and synthetic agents that manipulate pharmacologically the action at cannabinoid receptors or the tissue levels of AEA and 2-AG. SN - 1879-0402 UR - https://www.unboundmedicine.com/medline/citation/19497779/From_endocannabinoid_profiling_to_'endocannabinoid_therapeutics'_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1367-5931(09)00060-X DB - PRIME DP - Unbound Medicine ER -